Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, January 10, 2025

Fluimucil as a neuroprotective, is there anything new? Bibliometric study from 1996 to 2024

 Which of the 5 causes of the neuronal cascade of death in the first week is this addressing?

Neuroprotection is a useless word; it gives NO sense of urgency. If your doctor tells you they did nothing to stop the neuronal cascade of death in the first week thus letting hundreds of millions to billions of neurons die, you'd sue them for malpractice.

Fluimucil as a neuroprotective, is there anything new? Bibliometric study from 1996 to 2024

 [version 1; peer review: awaiting peer review]
ARMAN YURISALDI SALEH
https://orcid.org/0000-0001-5866-3585
1, Tirta Darmawan Susanto
https://orcid.org/0000-0002-4151-5946
2, Riezky Valentina1, Dwi Arwandi Yogi Saputra3
Author details

Abstract

Introduction

Fluimucil, also known as N-acetylcysteine (NAC), has been used as a medicinal drug for treating Alzheimer’s and Parkinson’s disease. Recent research has shown NAC’s potential as a neuroprotective agent, preventing oxidative damage and promoting neurodegenerative treatment. This study conducted bibliometric analysis of articles related to NAC use, identifying research trends, current trends, and correlations between research and institutions. The findings can help identify unpublished research and guide future research strategies. This research not only provides public interest in NAC research but also offers valuable insights for future research.

Methods

In this work, a literature review methodology is employed to gather data from the Scopus database using the keywords fluimucil, nac, n-acetylcystein, and neuroprotective. Data were analyzed using Biblioshiny and VOSviewer software to produce visualizations and bibliometric maps. We conducted quantitative and qualitative analysis.

Results

The research trend found are Documents by Year, Documents by Author, Documents by Affiliations, Documents by country or territory, Documents by funding sponsor, Factorial Map Of The Documents With The Highest Contributes, Documents by Subject Area, Network Visualization, Overlay visualization of scopus database using Vosviewer, Density Visualization, Thematic Map, and Qualitative Analysis.

Conclusions

Research on the neuroprotective effects of N-acetylcysteine (NAC) or fluimucil has several limitations and strengths. It uses quantitative and qualitative analysis to identify research trends and mechanisms of NAC action. However, the data may be biased and the methodology may differ. The study has significant potential for future research, particularly in treating neurodegenerative diseases like Parkinson and Alzheimer. It also contributes to the understanding of NAC mechanisms.

Keywords

Fluimucil, N-acetyl-cystein, NAC, neuroprotective, antioxidant, bibliometric, trend.

Corresponding author: ARMAN YURISALDI SALEH
Competing interests: No competing interests were disclosed.
Grant information: The author(s) declared that no grants were involved in supporting this work.
Copyright:  © 2025 SALEH AY et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite: SALEH AY, Susanto TD, Valentina R and Saputra DAY. Fluimucil as a neuroprotective, is there anything new? Bibliometric study from 1996 to 2024 [version 1; peer review: awaiting peer review]. F1000Research 2025, 14:46 (https://doi.org/10.12688/f1000research.156696.1) First published: 08 Jan 2025, 14:46 (https://doi.org/10.12688/f1000research.156696.1) Latest published: 08 Jan 2025, 14:46 (https://doi.org/10.12688/f1000research.156696.1)
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)